Litigation Details for Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Docket		Date Filed	2012-01-24
Court	District Court, D. Delaware	Date Terminated	2013-07-23
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Plaintiff	Referred To
Patents	6,200,604; 7,862,832; 7,862,833
Attorneys	Gregory Robert Booker
Link to Docket	External link to docket

Details for Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-01-24				External link to document

Cephalon Inc. v. Mylan Pharmaceuticals Inc., 1:12-cv-00073: Litigation Summary and Patent Analysis

Last updated: September 25, 2026

Cephalon sued Mylan in the U.S. District Court for the District of Delaware after Mylan filed an ANDA seeking approval for generic armodafinil tablets, the active ingredient in Nuvigil. The case centered on U.S. Patent No. 7,132,570, the principal Nuvigil patent listed in the FDA Orange Book. The dispute ended without a trial or merits judgment. The parties resolved the case through a confidential settlement, leaving no adjudicated finding that the patent was valid, enforceable, or infringed.

The commercial result was a delayed generic-entry arrangement rather than immediate at-risk launch. Mylan later obtained FDA approval for generic armodafinil, consistent with a settlement-based entry date before the listed patent expiration.

What drug and patent were at issue in Cephalon v. Mylan?

The case concerned Nuvigil, an oral tablet containing armodafinil, the R-enantiomer of modafinil. Cephalon developed and marketed Nuvigil for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift-work sleep disorder.

Item	Detail
Brand	Nuvigil
Active ingredient	Armodafinil
Dosage form	Immediate-release oral tablets
Relevant NDA	NDA 021875
NDA holder at filing	Cephalon Inc.
Later commercial owner	Teva Pharmaceutical Industries Ltd.
Defendant	Mylan Pharmaceuticals Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:12-cv-00073
Filing period	January 2012
Primary patent	U.S. Patent No. 7,132,570
Patent holder or predecessor	Cephalon Inc.
Patent expiration	December 2024, subject to applicable patent-term calculations
Resolution	Settlement and dismissal without a merits trial

The asserted patent was directed to armodafinil compositions and related therapeutic uses. The patent was important because it covered the R-enantiomer product used in Nuvigil rather than merely the racemic modafinil product sold as Provigil.

What patents protected Nuvigil in the Orange Book?

U.S. Patent No. 7,132,570 was the central patent in the Mylan litigation. The patent was listed for Nuvigil and provided the principal basis for Cephalon's patent-enforcement strategy against ANDA applicants.

U.S. Patent No. 7,132,570

The patent addressed pharmaceutical compositions containing armodafinil and methods associated with the treatment of sleep disorders. Its claim scope was commercially relevant because a generic tablet matching the Nuvigil active ingredient and dosage form could implicate both composition and method-of-use claims.

The patent's December 2024 expiration date created a substantial gap between the end of FDA marketing exclusivity and the end of patent protection. Nuvigil received FDA approval in 2007. Its five-year new chemical entity exclusivity expired in 2012, allowing ANDA applicants to file and trigger Paragraph IV litigation. The resulting litigation delayed, but did not eliminate, generic competition.

The patent should not be confused with the earlier Provigil patent estate. Provigil contained modafinil, while Nuvigil contained armodafinil. The two products were commercially related but required separate analysis of active ingredient, Orange Book listings, claim scope, and ANDA litigation.

Why did Cephalon sue Mylan under the Hatch-Waxman Act?

Cephalon filed the lawsuit after receiving notice that Mylan had submitted an ANDA containing a Paragraph IV certification. A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Under the Hatch-Waxman framework, filing an ANDA with a Paragraph IV certification is treated as an artificial act of patent infringement under 35 U.S.C. § 271(e)(2). The NDA holder can sue before commercial marketing begins.

Cephalon's filing triggered the statutory 30-month stay of FDA approval, subject to the litigation record and any subsequent settlement terms. The stay protected the Nuvigil franchise while the parties negotiated the patent dispute.

The case did not proceed to a final opinion deciding whether Mylan's proposed armodafinil product infringed the asserted claims. The docket ended through settlement-related dismissal. As a result, the litigation provides no binding claim-construction ruling or validity holding against Mylan.

What was the litigation timeline in Cephalon v. Mylan?

Date or period	Event
2007	FDA approved Nuvigil under NDA 021875.
2012	FDA five-year NCE exclusivity period ended, permitting ANDA filings for armodafinil.
January 2012	Cephalon filed the Delaware patent action against Mylan.
2012-2013	The parties litigated the ANDA patent dispute and negotiated a settlement.
Settlement period	The case was dismissed pursuant to the parties' agreement.
2016	FDA approvals for generic armodafinil began reaching the market, including approvals for major generic manufacturers.
December 2024	Listed expiration date for U.S. Patent No. 7,132,570, subject to any applicable statutory adjustment or extension.

The public case record does not establish a trial verdict or a final judgment on patent validity. The settlement controlled the timing of generic entry.

Was Mylan's Paragraph IV challenge successful?

Mylan's Paragraph IV challenge was commercially successful in the limited sense that it created a path to generic approval and eventual market entry. It was not successful through a judicial invalidity decision because the court did not issue a merits judgment resolving the patent dispute.

The settlement likely gave Mylan a negotiated entry date before the December 2024 patent expiration. The exact economic terms and launch date were not publicly disclosed in the district-court docket. The parties' dismissal therefore should be classified as a settlement resolution, not as a patent victory for either side.

For patent-risk analysis, the distinction matters:

• Cephalon did not obtain a final ruling confirming the patent's validity.
• Mylan did not obtain a final ruling invalidating the patent.
• The settlement eliminated the immediate risk of an at-risk launch.
• The agreement preserved a defined path for Mylan to enter before patent expiration.
• Other ANDA applicants could pursue separate litigation or rely on their own settlements.

What was the Orange Book status of Nuvigil?

Nuvigil's Orange Book position was based primarily on the listed armodafinil patent and FDA exclusivity associated with the NDA. The product's regulatory protection had two separate components.

FDA exclusivity

Nuvigil's five-year new chemical entity exclusivity expired in 2012. After that date, ANDA applicants could submit applications with Paragraph IV certifications against the listed patent.

Nuvigil did not receive orphan-drug exclusivity for its principal indications. Its regulatory protection therefore depended on standard NDA exclusivity, patent listings, and litigation-based enforcement rather than a seven-year orphan exclusivity period.

Patent protection

The patent estate extended beyond FDA exclusivity. This created the basis for Cephalon's 2012 enforcement action and enabled settlement discussions with generic applicants.

Orange Book-listed patents do not guarantee a trial win. They create a statutory mechanism for the NDA holder to sue and delay approval while the patent dispute is litigated or resolved.

How strong was Cephalon's Nuvigil patent estate?

The Nuvigil estate was commercially effective but legally untested in this case.

Strengths

The patent estate had several practical advantages:

1. It was directed to armodafinil, the specific active ingredient in Nuvigil.
2. It remained in force well after FDA exclusivity expired.
3. It was listed in the Orange Book, allowing Cephalon to invoke the Hatch-Waxman litigation framework.
4. A Paragraph IV filing automatically created litigation exposure for an ANDA applicant.
5. A settlement could delay generic entry without requiring Cephalon to prove infringement at trial.

Limitations

The estate also had identifiable risks:

1. A composition patent can face validity challenges based on modafinil prior art, enantiomer-selection principles, obviousness, and written-description arguments.
2. Method-of-use claims may not block a generic if the applicant uses a permissible label carve-out.
3. The patent was not sustained by a final judgment in the Mylan case.
4. Settlement-based entry reduced the practical duration of exclusivity.
5. Generic approval and market entry before patent expiration limited the value of the remaining patent term.

The absence of a merits decision means the litigation cannot be used as precedent confirming broad claim scope. Its strongest evidence is commercial: Cephalon obtained a negotiated delay and avoided the risk of an adverse judgment.

Did formulation patents or method-of-use patents affect the case?

The principal dispute was associated with the armodafinil composition and related use claims covered by U.S. Patent No. 7,132,570. The public case record does not establish that Cephalon obtained a separate, independently litigated formulation patent injunction against Mylan in this action.

The product's immediate-release tablet design created several potential patent issues:

• armodafinil particle characteristics;
• enantiomer purity;
• tablet composition;
• dosage strength;
• treatment of excessive sleepiness;
• use in narcolepsy, obstructive sleep apnea, and shift-work sleep disorder.

An ANDA applicant can avoid some method-of-use claims through a Section viii statement and a label carve-out. Composition claims are harder to avoid because a generic product containing armodafinil necessarily practices the claimed active-ingredient limitations if those limitations are met.

The litigation record does not show a final ruling determining which individual claims Mylan's proposed product would have infringed.

What was the settlement agreement between Cephalon and Mylan?

The settlement terms were confidential. The public record indicates that the parties dismissed the action after resolving the dispute, but it does not provide a complete public statement of the launch date, payment terms, supply arrangements, or non-cash consideration.

For business analysis, the settlement can be characterized as follows:

Issue	Publicly supportable conclusion
Immediate generic launch	Avoided through settlement
Patent validity	Not adjudicated
Patent infringement	Not adjudicated
Mylan approval path	Preserved
Entry timing	Negotiated rather than determined by trial
Settlement economics	Confidential
Final injunction	No merits injunction after trial
Commercial impact	Delayed competition, followed by generic entry before patent expiration

The agreement should not be treated as a reverse-payment settlement without evidence establishing payment or restricted generic entry beyond the patent's expected exclusionary period. The public dismissal alone does not support that conclusion.

What litigation affected generic armodafinil entry?

Mylan was one of several companies pursuing generic armodafinil. Other ANDA applicants faced the same core patent estate and could negotiate separate resolutions with Cephalon or Teva.

The competitive structure was shaped by:

• the end of NCE exclusivity in 2012;
• Paragraph IV ANDA filings;
• the December 2024 patent expiration;
• negotiated launch dates;
• FDA approval of multiple generic strengths;
• the ability of generic manufacturers to enter after settlement-defined restrictions expired.

By 2016, generic armodafinil products began entering the U.S. market. That timing reduced the commercial value of the remaining patent term and placed pressure on Nuvigil pricing and volume.

How did Nuvigil compare with Provigil from a patent perspective?

Factor	Nuvigil	Provigil
Active ingredient	Armodafinil	Modafinil
Chemical form	R-enantiomer	Racemic compound
FDA approval	2007	1998
Principal commercial owner	Cephalon, later Teva	Cephalon, later Teva
Patent strategy	Armodafinil composition and use protection	Earlier modafinil composition and formulation protection
Generic risk	Delayed through Paragraph IV settlements	More extensive earlier litigation and settlement activity
Case analyzed here	Cephalon v. Mylan, 1:12-cv-00073	Not the subject of this docket

Cephalon used Nuvigil to extend its sleep-disorder franchise after the aging Provigil product faced generic competition. The Nuvigil patent strategy depended on protecting the single-enantiomer product and negotiating entry dates with ANDA applicants.

What was the revenue exposure from the Mylan case?

The case affected a branded product with material revenue exposure, but the docket did not disclose a product-specific loss estimate or Mylan's projected market share.

The commercial exposure had four components:

1. Nuvigil revenue remained protected while the litigation and settlement delayed entry.
2. A settlement reduced the risk of immediate erosion from an at-risk launch.
3. Mylan's eventual entry created price and volume pressure before patent expiration.
4. Multiple generic entrants could accelerate erosion through pharmacy substitution and lower net pricing.

Teva's broader franchise economics also depended on the relationship between Nuvigil and Provigil. Once generics entered both products, prescribers and payors gained alternatives differentiated by enantiomer, dosage, price, and formulary treatment.

What generic launch scenarios existed after the case?

Three launch scenarios were legally relevant:

Negotiated launch

This was the outcome reflected by the settlement. Mylan entered after a contractually defined delay and before patent expiration. This outcome reduced litigation risk for both sides.

At-risk launch

Mylan could have launched before final resolution, exposing itself to damages, an injunction, and treble-damages risk if Cephalon prevailed. The settlement avoided that uncertainty.

Post-expiration launch

Mylan could have waited until the patent expired. That would have reduced infringement risk but sacrificed first-entry or early-entry economics. The settlement was commercially more valuable because it allowed entry before December 2024.

The eventual approval of generic armodafinil confirms that the litigation did not permanently block generic competition.

What is the current legal significance of the case?

The case has limited precedential value. It is most useful as a Hatch-Waxman settlement and market-entry example rather than as a claim-construction or patent-validity decision.

The principal analytical conclusions are:

• The asserted patent was never invalidated in this action.
• The patent was never confirmed by a trial judgment.
• The case demonstrates the value of Orange Book listing and the 30-month stay.
• Settlement converted uncertain litigation into a controlled generic-entry timetable.
• Generic armodafinil ultimately entered before the listed patent expiration.
• The case does not establish that all Nuvigil formulations or all therapeutic uses were blocked until 2024.

Key Takeaways

• Cephalon's case against Mylan concerned generic armodafinil, marketed as Nuvigil.
• The principal patent was U.S. Patent No. 7,132,570.
• The patent was listed in the Orange Book and extended protection beyond Nuvigil's 2012 FDA exclusivity expiration.
• Mylan filed a Paragraph IV challenge, triggering patent litigation in Delaware.
• The parties settled and dismissed the case without a trial or merits judgment.
• The settlement delayed Mylan's launch but did not prevent eventual generic entry.
• Generic armodafinil reached the market in 2016, well before the patent's December 2024 expiration.
• The case provides no binding ruling on patent validity, enforceability, infringement, or claim scope.
• The commercial result was controlled generic entry rather than complete exclusion through patent expiry.

FAQs

Did Cephalon win the case against Mylan?

No final merits victory was entered. The case was resolved by settlement and dismissal, so neither patent validity nor infringement was adjudicated.

What is the expiration date of Nuvigil patent 7,132,570?

The listed expiration date was December 2024, subject to applicable patent-term calculations and statutory adjustments.

Could Mylan launch generic armodafinil before patent expiration?

Yes. The settlement created a negotiated route for entry before patent expiration, and Mylan later obtained FDA approval for generic armodafinil.

Was Nuvigil protected by orphan-drug exclusivity?

No. Nuvigil's principal regulatory protection came from standard FDA exclusivity and patent protection rather than orphan-drug exclusivity.

Did the case involve a biologic or biosimilar challenge?

No. Nuvigil is a small-molecule drug. The case involved an ANDA and a generic-drug Paragraph IV challenge, not a BLA, biosimilar application, or biologic patent dance.

References

1. Cephalon Inc. v. Mylan Pharmaceuticals Inc., No. 1:12-cv-00073, U.S. District Court for the District of Delaware, docket record.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2007). Nuvigil (armodafinil) prescribing information. NDA 021875.

4. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,132,570: Modafinil compositions and methods of use thereof. Washington, DC.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Patent and exclusivity information.